Lawrence J. Jasinski - Dec 1, 2022 Form 4 Insider Report for LEMAITRE VASCULAR INC (LMAT)

Role
Director
Signature
/s/ Laurie A. Churchill, Attorney-in-fact
Stock symbol
LMAT
Transactions as of
Dec 1, 2022
Transactions value $
-$136,647
Form type
4
Date filed
12/5/2022, 07:06 PM
Previous filing
Sep 12, 2022
Next filing
Dec 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LMAT Common Stock Options Exercise $58.9K +2.5K +28.06% $23.56 11.4K Dec 2, 2022 Direct F1
transaction LMAT Common Stock Options Exercise $88.7K +2.5K +21.91% $35.48 13.9K Dec 2, 2022 Direct F1
transaction LMAT Common Stock Options Exercise $186K +5K +35.95% $37.29 18.9K Dec 2, 2022 Direct F1
transaction LMAT Common Stock Sale -$471K -10K -52.88% $47.07 8.91K Dec 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LMAT Dividend Equivalent Rights Award $0 +1.53 +50.88% $0.00 4.53 Dec 1, 2022 Common Stock 1.53 Direct F3
transaction LMAT Stock Option (Right to Buy) Options Exercise $0 -2.5K -100% $0.00* 0 Dec 2, 2022 Common Stock 2.5K $23.56 Direct F4
transaction LMAT Stock Option (Right to Buy) Options Exercise $0 -2.5K -50% $0.00 2.5K Dec 2, 2022 Common Stock 2.5K $35.48 Direct F5
transaction LMAT Stock Option (Right to Buy) Options Exercise $0 -5K -66.67% $0.00 2.5K Dec 2, 2022 Common Stock 5K $37.29 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
F2 The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $47.00 to $47.23. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
F3 These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F4 This option is fully vested and exercisable.
F5 This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.